

## **Glutathione Reductase Is Inhibited by Acetaminophen-glutathione Conjugate *in vitro***

TOMÁŠ ROUŠAR<sup>1,2</sup>, PATRIK PAŘÍK<sup>3</sup>, OTTO KUČERA<sup>1</sup>, MARTIN BARTOŠ<sup>4</sup> &  
ZUZANA ČERVINKOVÁ<sup>1</sup>

<sup>1</sup> *Dept. of Physiology, Faculty of Medicine in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic;* <sup>2</sup> *Dept. of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic;* <sup>3</sup> *Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic;* <sup>4</sup> *Dept. of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic.*

### *Correspondence:*

Mgr. Tomáš Roušar, Ph.D.

Dept. of Physiology  
Faculty of Medicine in Hradec Králové, Charles University in Prague  
Šimkova 870  
500 38 Hradec Králové  
Czech Republic  
E-mail: Tomas.Rousar@upce.cz  
Tel: (+420) 466037707  
Fax: (+420) 495518772

*Short title:* Inhibition of glutathione reductase by APAP-SG *in vitro*

## Summary

The aim of the present work was to investigate a new mechanism likely contributing to the toxic action of acetaminophen especially to explore the possible inhibition of glutathione reductase through an acetaminophen-glutathione conjugate (APAP-SG). APAP-SG conjugate was synthesized by organic synthesis and purified by column chromatography. The inhibitory effect of the conjugate on two types of glutathione reductase (from yeasts and rat hepatocytes) was tested spectrophotometrically. We found that the enzyme activity was reduced similarly after treatment with 2.96 mM acetaminophen-glutathione conjugate in both yeast and hepatocyte glutathione reductases (GR); the enzyme activity was inhibited to  $52.7 \pm 1.5$  % ( $2.4 \pm 0.3$  mU/ml) in yeast GR (control activity was  $5.6 \pm 0.3$  mU/ml) and to  $48.1 \pm 8.8$  % ( $2.2 \pm 0.2$  mU/ml) in rat hepatocytes lysate GR (control activity was  $5.2 \pm 0.2$  mU/ml). In addition, the enzyme activity (from hepatocytes lysate) was decreased to  $79 \pm 7$  %,  $67 \pm 2$  % and  $39 \pm 7$  %, in 0.37, 1.48 and 3.7 mM concentration of the conjugate, respectively. We found that glutathione reductase, the essential enzyme of the antioxidant system, was dose-dependently inhibited by the product of acetaminophen metabolism – the conjugate of acetaminophen and glutathione.

**Keywords:** acetaminophen toxicity; glutathione reductase; glutathione; hepatotoxicity.

## Introduction

Acetaminophen (APAP) is at present one of the mostly used analgesics and antipyretics. It is considered to be a safe drug when used at therapeutic doses. On the other hand, the acetaminophen overdosing is the most frequent cause of acute liver failure in men (Lee 2004). Hence, the mechanisms of acetaminophen toxicity have been studied very intensively recently.

At therapeutic doses, acetaminophen is detoxified by three major pathways in the liver. The most of APAP dose is conjugated with glucuronate and sulfate (about 80% and 10%, respectively). Remaining part of APAP is oxidized by cytochrome P450 to a toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI). This compound is detoxified by either spontaneous or enzyme-catalyzed reaction with glutathione (GSH) resulting in a conjugate, 3-(glutathion-S-yl)acetaminophen (APAP-SG). In APAP overdose, the glucuronidation and sulfation pathways are saturated, acetaminophen is being oxidized to NAPQI in much higher extent and GSH stores become depleted. Consequently, NAPQI binds to various proteins, the APAP-protein adducts are produced, and due to GSH depletion, there is an increase of oxidative stress in the cell (Jollow *et al.* 1973). These actions result in hepatocellular death seen as centrilobular necrosis in the liver (Jaeschke and Bajt 2006; Mitchell *et al.* 1973). So far, numerous mechanisms contributing to the hepatocyte injury have been found. Except of GSH depletion and reactive oxygen species (ROS) production, the lipoperoxidation, mitochondrial permeability transition pore opening (Kon *et al.* 2004) and impairment of mitochondrial respiration have also been mentioned. Despite the processes cited above, the crucial causation of the toxicity remains unknown (Jaeschke and Bajt 2006; Kaplowitz 2004). Till now, two possible theories have been postulated – the oxidative and the metabolic one. The oxidative theory proposes the explanation of the damage by an increase of oxidative

stress, the latter one by binding of NAPQI to SH-groups of proteins supposing their function to be impaired (James *et al.* 2003). Unfortunately, neither the oxidative nor the latter theory explain the entire toxicity found in acetaminophen treated liver cells at all points.

As we have recently described (Rousar *et al.* 2009), acetaminophen toxicity is linked to reduced activity of glutathione reductase (GR) *in vitro*. It is a crucial enzyme in glutathione metabolism because it reduces glutathione disulphide (GSSG) back to the reduced form, GSH. Thus, this enzyme is essentially important during oxidative stress, where the level of GSSG increases and the inhibition of glutathione reductase could be a principal mechanism in acetaminophen toxicity. Since the cause of the enzyme inhibition remains unknown, the aim of our work is focused on an attempt to find and describe the reason of decreased activity of glutathione reductase (using two different types of glutathione reductases, i.e. from yeast and from rat hepatocytes); and especially, to prove the hypothesis that APAP-SG conjugate may play an important role in the mechanism of APAP toxicity. The experiments were carried out *in vitro*. The outcomes were aimed to serve as the preliminary data for following testing in cells and *in vivo*.

## **Materials and Methods**

### *Chemicals*

Glutathione reductase (from *Sacch. cerevisiae*; 160 U/mg prot.), GSH, glutathione disulphide, sodium phosphate buffer, potassium phosphate buffer, hydrochloric acid, acetaminophen and NADPH were purchased from Sigma-Aldrich (USA). The reagents used to the synthesis and purification of APAP-SG conjugate were purchased from Lachema (Czech Republic)

### *Preparation of acetaminophen-glutathione conjugate*

The APAP-SG conjugate was synthesized according to the method of Thatcher and Murray (2001), the separation of the conjugate was performed as a modification of the method described by Allameh and Alikhani (2002). Briefly, sodium hydroxide solution (8 g in 250 ml of distilled water) was added to the solution of silver nitrate (4.224 g in 65 ml of distilled water) and the precipitated silver oxide was filtered off using glass sinter and washed. Acetaminophen (0.428 g) was suspended in 100 ml of dry chloroform and just prepared silver oxide (2.2 g) was added. The suspension was stirred, filtered and the NAPQI solution was obtained. Glutathione (0.857 g) was dissolved in 250 ml of 0.1 M sodium phosphate buffer pH 7.4 and freshly prepared NAPQI solution was added drop wise. Reaction mixture was separated and the water was evaporated at 40 °C. Residue of the mixture was stirred in methanol for 3 h and filtered. Methanol was evaporated using vacuum evaporator. APAP-SG conjugate was separated using column chromatography on Silicagel 60 (Merck, Germany) where the separation of the reaction residue containing APAP, APAP-SG and GSSG was performed; mobile phase consisted of methanol/water (9:1). The fractions (10 ml) were collected after separation and analyzed by thin layer chromatography (TLC) according to Allameh and Alikhani (2002). The detection was carried out using TLC on Silicagel 60 F254 (Merck, Germany) with methanol/water (9:1) as a mobile phase; bands were visualized by  $\lambda = 254$  nm (APAP, APAP-SG) or after reaction with 0.2 % ninhydrin (APAP-SG, GSSG). The R<sub>f</sub> values for APAP, APAP-SG and GSSG were approximately 0.9, 0.7 and 0.3, respectively. The R<sub>f</sub> values of GSSG and APAP were determined after comparison with standard values. APAP-SG conjugate was obtained as a solid by desiccation of the fractions with proved APAP-SG only.

### *Preparation of hepatocyte lysates*

Hepatocytes were isolated from male albino Wistar rats (250-280 g; Biotest, Czech Republic) by collagenase perfusion (Berry *et al.* 1991). The viability of freshly isolated hepatocytes was more than 90 % as confirmed by trypan blue exclusion. Isolated hepatocytes were suspended in Williams' E medium and diluted to final density of  $10^6$  cells per ml. The cells were sonicated (Bandelin Sonopuls sonicator, Germany) and the lysates were centrifuged (4°C, 10 min, 10000 g). The inhibition of glutathione reductase was tested in supernatant which was diluted in distilled water to gain the final GR activity similar to samples containing yeast glutathione reductase. (The specific activity of rat hepatocytes lysate GR was 22 mU/mg prot.) All animals received care according to the guidelines set by the Institutional Animal Use and Care Committee of the Charles University, Prague, Czech Republic.

### *GR activity assay*

The principle of the method is the reduction of oxidized glutathione by glutathione reductase in the presence of NADPH (Carlberg and Mannervik 1975). Activity of both yeast (from *Sacch. cerevisiae*; 160 U/mg prot.) and hepatocytes lysate GR was determined at 25 °C in 0.2 M potassium phosphate buffer (pH 7.5) by monitoring of NADPH absorbance decline ( $\lambda = 340$  nm) using well-plate spectrophotometer INFINITE M200 (Tecan, Austria). The volumes of solutions were 50  $\mu$ l GR, 25  $\mu$ l GSSG (3.7 mM) and the assay was started by addition of 50  $\mu$ l NADPH (0.7 mM); the values in the brackets mean the final concentrations of a compound in a well. The decline of absorbance was monitored during 20 minutes and the results were presented as a dependence of absorbance ~ time. (1 Unit was defined as an amount of the enzyme which will reduce 1  $\mu$ mole of oxidized glutathione per minute at pH 7.6 at 25 °C, using a molar extinction coefficient of  $6.22 \times 10^3$  for NADPH.).

### *Estimation of GR inhibition by APAP-SG conjugate*

The inhibition of both yeast and rat hepatocytes lysate GR activities by APAP-SG conjugate were assayed in well plates. The stock solution of APAP-SG (100 mM) was prepared. Then, the solutions with various concentrations of APAP-SG (5 mM, 10 mM, 20 mM, 40 mM, 50 mM) were prepared by dilution in distilled water. 10  $\mu$ l of each solution were added to the mixture of GR (50  $\mu$ l) and GSSG (25  $\mu$ l) to assess the inhibitory effect. The measurement was started by addition of NADPH (50  $\mu$ l) and monitored by  $\lambda = 340$  nm spectrophotometrically for 20 minutes at 25 °C. Control samples were prepared by identical protocol, the distilled water (10  $\mu$ l) was added instead of APAP-SG conjugate.

### *Statistical analysis*

All experiments were repeated at least two times with negligible differences among results. The results were processed by one-way ANOVA test, followed by Bonferroni post-test. The results are expressed as the mean  $\pm$  SD (GraphPad Prism 4.03 for Windows, GraphPad Software, USA).  $p < 0.05$  was considered as significant.

## **Results**

Purified APAP-SG conjugate was used to estimation of possible inhibitory effect in two types of glutathione reductase – yeast and from rat hepatocytes lysate. The results show (Fig. 1) that the activity of both types of GR was decreased similarly in comparison to control in the presence of 2.96 mM APAP-SG. The enzyme activity was inhibited to  $52.7 \pm 1.5$  % ( $2.4 \pm 0.3$  mU/ml) in yeast GR (control activity was  $5.6 \pm 0.3$  mU/ml) and to  $48.1 \pm 8.8$  % ( $2.2 \pm 0.2$  mU/ml) in rat hepatocytes lysate GR (control activity was  $5.2 \pm 0.2$  mU/ml). Based on these results, all other experiments were performed using rat liver GR.

We analyzed also blank samples in all experiments. The blank samples did not contain GSSG and the obtained absorbance signals were subtracted in both control and APAP-SG-treated samples. The results show that the blank signal accounts for only 2 % and 4 % of absorbance decrease in control and APAP-SG-treated samples, respectively (Fig. 2). Although we did not purified the hepatocyte GR, the values of blank signals showed, that our conditions of GR assay were rather specific.

The inhibitory effect on hepatocyte glutathione reductase was tested in a number of APAP-SG concentrations. We found, that the enzyme activity was decreased proportionally related to increasing APAP-SG concentration (Fig. 3). The GR activity was inhibited to  $79.8 \pm 7.0$  %,  $72.1 \pm 0.5$  %,  $66.9 \pm 2.2$  %,  $48.0 \pm 7.1$  % and  $39.5 \pm 7.4$  % in presence of 0.37 mM, 0.74 mM, 1.48 mM, 2.96 mM and 3.7 mM APAP-SG, respectively. (GR activity in controls was  $8.7 \pm 0.5$  mU/ml.)

## **Discussion**

Acetaminophen toxicity is a complex process where many mechanisms contribute to the hepatocyte impairment. Since the acetaminophen overdosing is one of the mostly found causations of acute liver failure (Lee 2004), the estimation of APAP toxicity has been extensively studied.

Recently in this field, a number of reviews and original papers have been published in which new mechanisms contributing to the liver damage have been described. However, none of the mechanisms explain the cause of the hepatocyte damage completely (Jaeschke and Bajt 2006; James *et al.* 2003).

The former assumption explaining a cause of APAP toxicity is a metabolic one. It is linked to increased NAPQI production during metabolic phase in the APAP overdose. After GSH stores are depleted, NAPQI binds to various proteins and the APAP-adducts are produced



(Jollow *et al.* 1973; Qiu *et al.* 1998). This was believed to impair the protein function.

However, none or only a modest change in their activity was found (Pumford *et al.* 1997).

The proposal of the oxidative theory is that the GSH depletion is followed by enhanced oxidative stress in a short period of time which leads to the hepatocyte injury. Indeed, it was supported by increased lipoperoxidation, ROS production or increased synthesis of nitric oxide (NO) (Hinson *et al.* 1998; Jaeschke *et al.* 2003; Knight *et al.* 2001). However, it is questioned if the oxidative stress is a cause or just a consequence to decreased glutathione levels. It was shown that the increased ROS production follows the GSH depletion (Bajt *et al.* 2004). Another issue was to determine the localization of ROS production. The role of Kupffer cells, increased NO production or mitochondria as a source of ROS were investigated. Nevertheless, the answer to the role of ROS as the main cause of cell death has not been confirmed definitely yet (Jaeschke and Bajt 2006; James *et al.* 2003).

The present work is directed to assess a newly proposed principle contributing to the acetaminophen toxicity. We observed recently that the glutathione reductase activity was reduced in rat hepatocytes treated with acetaminophen (Rousar *et al.* 2009). This inhibition was proved to be dose-dependent. We ascribed the reason of GR inhibition to impairment of the enzyme by ROS or toxic aldehydes, as described in several published papers (Ochi 1990; Vessey and Lee 1993). Despite this, we have proposed another theory of the cause of GR inhibition. We have hypothesized that the inhibition could be caused by direct effect of APAP-SG, the conjugate of glutathione and acetaminophen (or NAPQI more precisely). To prove our hypothesis, we decided to prepare APAP-SG conjugate by organic synthesis. We tested two types of glutathione reductase – a commercially available GR from yeast *Sacch. cerevisiae* and GR from rat hepatocytes lysate. In accordance to our hypothesis, we repeatedly observed after analysis of the experimental data, that APAP-SG inhibits largely

yeast and hepatocytes lysate GR; 2.96 mM APAP-SG was able to inhibit glutathione reductase activity by about 50%.

The assessed concentrations of APAP-SG (0.37 – 3.7 mM) may be comparable to the APAP-SG levels occurring in hepatocytes. In APAP overdose, the levels of APAP in the cells are in milimolar range (Mitchell *et al.* 1973); the GSH levels in hepatocytes are found in milimolar range as well (Pastore *et al.* 2003). After the glucuronidation and sulfation pathways are saturated, the most of the dose is oxidized to NAPQI. Thus, here described effect of APAP-SG on the GR activity is likely to occur in the cells. The possibly substantial role of GR in the acetaminophen toxicity is supported by the work of Armesto *et al.* (Armesto *et al.* 1993) who demonstrated that a drug, lobenzarit, enhances GR activity in mice. Since lobenzarit was proved to have hepatoprotective properties in APAP overdose, this effect may be caused just by decreasing of the GR inhibition present in APAP-treated hepatocytes.

We propose, the cause of observed GR inhibition by APAP-SG might be due to similar principle as in case of inhibition of glutathione reductase by S-nitrosoglutathione (Becker *et al.* 1995). The authors presented that S-nitrosoglutathione was capable of inhibiting the glutathione reductase activity by reversible and/or irreversible mechanism. It follows, that GR is able to react with a compound of chemical structure related at least to a half of glutathione disulphide molecule.

The exploration of glutathione reductase inhibition by APAP-SG changes the view to acetaminophen toxicity in part. Indeed, the conjugate of acetaminophen (or more precisely NAPQI) and glutathione occurs always once NAPQI has been formed by cytochrome P450. Moreover, NAPQI production is even catalyzed by glutathione-S-transferase (GST) (Coles *et al.* 1988). The conjugation of APAP and GSH has been considered till now as a protective mechanism which protects the hepatocyte against the binding of NAPQI to various proteins. The conjugate is consequently transported out of the cell to the bile by MRP-2 (Multidrug

resistance-associated protein-2) localized in the canalicular membrane of hepatocyte (Chen *et al.* 2003).

Despite generally accepted mechanisms described above, several original works published results that were not anticipated before. In 2000, the work of Henderson *et al.* described the estimation of APAP toxicity in GST-pi knockout mice (Henderson *et al.* 2000). GST-pi is an isoenzyme of glutathione-S-transferase which is proved to catalyze the formation of APAP-SG conjugate in the liver (Coles *et al.* 1988; Henderson and Wolf 2005). Remarkably, the results showed that GST-pi knockout mice were much more resistant to APAP toxicity than wild-type mice. The explanation of that phenomenon was attributed to GST-catalyzed redox cycling and enhancement of oxidative stress, or to the role of GST-pi as an inhibitor of the stress inducible Jun N-terminal kinase (Henderson *et al.* 2000). However, the results may be explained convincingly regarding the finding published in this paper.

The hepatocytes from mice lacking GST-pi produce much lower amount of APAP-SG conjugate certainly (Coles *et al.* 1988). Hence, lower concentration of APAP-SG can lead to slighter inhibition of GR; indeed, this is supported by different recoveries of glutathione after comparison of wild-type and GST-pi knockout mice treated with acetaminophen (Henderson *et al.* 2000). The results showed that GSH concentrations were decreased in both of strains although GSH levels remained higher at all time points in knockout mice compared to wild-type. In addition, the GSH levels recovered to near pretreatment levels within 5 h in GST-pi null mice, however, GSH remained depleted in wild-type mice. The authors tested the protein levels of glutathione biosynthetic enzymes,  $\gamma$ -glutamylcysteine synthetase and glutathione synthetase, which were essentially unchanged. Hence, the GSH recovery cannot be explained in this way and it is likely that the diverse GSH recovery between mice strains could be influenced by different GR activity.

Another work was concerned in testing of susceptibility of transport-deficient hyperbilirubinemic, MRP-2 deficient rats to acetaminophen (Silva *et al.* 2005). The treatment of MRP-2 deficient rats with acetaminophen resulted in a finding that mutant rats were more resistant than wild-type of rats. The published explanation was that increased expression of certain cytochrome P-450 isoenzymes produced even more NAPQI which caused even larger impairment. On the other hand, the MRP-2 deficiency in rats likely evoked an accumulation of APAP-SG in the hepatocytes leading to the subsequent deepening of the GR inhibition (Silva *et al.* 2005). Obviously, an attribute of enhanced NAPQI formation is important too, but the increased toxicity may be due to increased production of APAP-SG again.

For further support of our hypothesis, we sought to find another mechanism capable to enhance APAP-SG intracellular levels. In 2000, a published work focused on estimation of acute APAP toxicity in transgenic mice with elevated hepatic glutathione (Rzucidlo *et al.* 2000). They hypothesized that due to overexpression of glutathione synthetase and elevated GSH levels, the transgenic mice should be better protected against APAP toxicity.

Surprisingly, the expectations were not fulfilled because transgenic mice showed significantly higher level of hepatotoxicity. The cause of this surprising finding was not fully explained again. However, regarding our results presented here, the mechanism of higher hepatotoxicity level in mice with elevated glutathione would be easily explainable by increased formation of APAP-SG conjugate and augmented inhibition of glutathione reductase.

## **Conclusions**

The obtained results confirmed our hypothesis that glutathione reductase could be inhibited by APAP-SG conjugate in vitro which is supported by published results of the other authors. Generally, depletion of GSH due to reaction with NAPQI in acetaminophen overdose is

always related to acetaminophen toxicity. Since glutathione reductase is a crucial enzyme in maintenance of intracellular GSH levels, the decrease of GR activity raises hepatocyte impairment. In addition, it is generally accepted that the GSH exhaustion results in a number of consequent pathological processes (e.g. ROS production, peroxynitrite formation and/or lipoperoxidation) which lead to GSSG production and to the cell death. Hence, we conclude that we shed light on a mechanism that could contribute to the acetaminophen toxicity in the liver.

### **Acknowledgement:**

This work was supported by grants of Ministry of Education, Youth and Sport of the Czech Republic (MSM0021627502, MSM0021620820) and Charles University Grant Agency (GAUK 90/2006). Great thanks belong to O. Štarman for support.

### **Abbreviations:**

APAP, acetaminophen; APAP-SG, acetaminophen-glutathione conjugate; GR, glutathione reductase; GSH, glutathione (reduced form); GSSG, glutathione disulphide; GST, glutathione-S-transferase; MRP-2, multidrug resistance-associated protein-2; NAPQI, N-acetyl-p-benzoquinone imine; ROS, reactive oxygen species; TLC, thin layer chromatography.

## References

- ALLAMEH A, ALIKHANI N: Acetaminophen-glutathione conjugate formation in a coupled cytochrome P-450-glutathione S-transferase assay system mediated by subcellular preparations from adult and weanling rat tissues. *Toxicol In Vitro* **16**: 637-641, 2002.
- ARMESTO J, FRUTOS N, GONZALEZ R, PASCUAL C: In vitro activation of hepatic glutathione reductase from mice by lobenzarit disodium. *Agents Actions* **39**: 69-71, 1993.
- BAJT ML, KNIGHT TR, LEMASTERS JJ, JAESCHKE H: Acetaminophen-induced oxidant stress and cell injury in cultured mouse hepatocytes: protection by N-acetyl cysteine. *Toxicol Sci* **80**: 343-349, 2004.
- BECKER K, GUI M, SCHIRMER RH: Inhibition of human glutathione reductase by S-nitrosoglutathione. *Eur J Biochem* **234**: 472-478, 1995.
- BERRY M, EDWARDS A, BARRITT G: High-yield preparation of isolated hepatocytes from rat liver. In R. BURDON and P. VAN KNIPPENBERG (eds.): *Isolated Hepatocytes Preparation, Properties and Application*, pp. 15-81, Elsevier, New York, 1991
- CARLBERG I, MANNERVIK B: Purification and characterization of the flavoenzyme glutathione reductase from rat liver. *J Biol Chem* **250**: 5475-5480, 1975.
- COLES B, WILSON I, WARDMAN P, HINSON JA, NELSON SD, KETTERER B: The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. *Arch Biochem Biophys* **264**: 253-260, 1988.
- HENDERSON CJ, WOLF CR: Disruption of the glutathione transferase pi class genes. *Methods Enzymol* **401**: 116-135, 2005.
- HENDERSON CJ, WOLF CR, KITTERINGHAM N, POWELL H, OTTO D, PARK BK: Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. *Proc Natl Acad Sci U S A* **97**: 12741-12745, 2000.
- HINSON JA, PIKE SL, PUMFORD NR, MAYEUX PR: Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. *Chem Res Toxicol* **11**: 604-607, 1998.
- CHEN C, HENNIG GE, MANAUTOU JE: Hepatobiliary excretion of acetaminophen glutathione conjugate and its derivatives in transport-deficient (TR-) hyperbilirubinemic rats. *Drug Metab Dispos* **31**: 798-804, 2003.
- JAESCHKE H, BAJT ML: Intracellular signaling mechanisms of acetaminophen-induced liver cell death. *Toxicol Sci* **89**: 31-41, 2006.
- JAESCHKE H, KNIGHT TR, BAJT ML: The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. *Toxicol Lett* **144**: 279-288, 2003.
- JAMES LP, MAYEUX PR, HINSON JA: Acetaminophen-induced hepatotoxicity. *Drug Metab Dispos* **31**: 1499-1506, 2003.
- JOLLOW DJ, MITCHELL JR, POTTER WZ, DAVIS DC, GILLETTE JR, BRODIE BB: Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. *J Pharmacol Exp Ther* **187**: 195-202, 1973.
- KAPLOWITZ N: Acetaminophen hepatotoxicity: what do we know, what don't we know, and what do we do next? *Hepatology* **40**: 23-26, 2004.
- KNIGHT TR, KURTZ A, BAJT ML, HINSON JA, JAESCHKE H: Vascular and hepatocellular peroxynitrite formation during acetaminophen toxicity: role of mitochondrial oxidant stress. *Toxicol Sci* **62**: 212-220, 2001.
- KON K, KIM JS, JAESCHKE H, LEMASTERS JJ: Mitochondrial permeability transition in acetaminophen-induced necrosis and apoptosis of cultured mouse hepatocytes. *Hepatology* **40**: 1170-1179, 2004.

- LEE WM: Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. *Hepatology* **40**: 6-9, 2004.
- MITCHELL JR, JOLLOW DJ, POTTER WZ, DAVIS DC, GILLETTE JR, BRODIE BB: Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. *J Pharmacol Exp Ther* **187**: 185-194, 1973.
- OCHI T: Effects of an organic hydroperoxide on the activity of antioxidant enzymes in cultured mammalian cells. *Toxicology* **61**: 229-239, 1990.
- PASTORE A, FEDERICI G, BERTINI E, PIEMONTE F: Analysis of glutathione: implication in redox and detoxification. *Clin Chim Acta* **333**: 19-39, 2003.
- PUMFORD NR, HALMES NC, MARTIN BM, COOK RJ, WAGNER C, HINSON JA: Covalent binding of acetaminophen to N-10-formyltetrahydrofolate dehydrogenase in mice. *J Pharmacol Exp Ther* **280**: 501-505, 1997.
- QIU Y, BENET LZ, BURLINGAME AL: Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. *J Biol Chem* **273**: 17940-17953, 1998.
- ROUSAR T, KUCERA O, KRIVÁKOVÁ P, LOTKOVÁ H, KANDÁR R, MUZÁKOVÁ V, CERVINKOVÁ Z: Evaluation of oxidative status in acetaminophen treated rat hepatocytes in culture. *Physiol Res* **58**: 2009. (in press)
- RZUCIDLO SJ, BOUNOUS DI, JONES DP, BRACKETT BG: Acute acetaminophen toxicity in transgenic mice with elevated hepatic glutathione. *Vet Hum Toxicol* **42**: 146-150, 2000.
- SILVA VM, THIBODEAU MS, CHEN C, MANAUTOU JE: Transport deficient (TR-) hyperbilirubinemic rats are resistant to acetaminophen hepatotoxicity. *Biochem Pharmacol* **70**: 1832-1839, 2005.
- THATCHER NJ, MURRAY S: Analysis of the glutathione conjugate of paracetamol in human liver microsomal fraction by liquid chromatography mass spectrometry. *Biomed Chromatogr* **15**: 374-378, 2001.
- VESSEY DA, LEE KH: Inactivation of enzymes of the glutathione antioxidant system by treatment of cultured human keratinocytes with peroxides. *J Invest Dermatol* **100**: 829-833, 1993.

**Fig. 1.** Comparison of inhibitory effect of acetaminophen-glutathione conjugate, APAP-SG (2.96 mM) on glutathione reductases from yeast and rat hepatocytes lysate. Glutathione reductases from yeast and rat hepatocytes were treated with a solution consisting of 2.96 mM APAP-SG conjugate (grey columns) and the decrease in absorbance ( $\lambda = 340$  nm) was measured after addition of NADPH for 20 minutes. The results were evaluated and compared to control (white columns) which consisted of the same concentrations of all compounds, excluding APAP-SG conjugate. Results are expressed as mean  $\pm$  SD. (n = 4; \*\*\*, p < 0.001, compared to control)

**Fig. 2.** Time course of the inhibition of glutathione reductase (from rat hepatocytes lysate) by acetaminophen-glutathione conjugate, APAP-SG (2.96 mM). Glutathione reductase (8 mU/ml) was treated with 2.96 mM APAP-SG conjugate ( $\circ$ , open circles) and the decrease in absorbance of NADPH ( $\lambda = 340$  nm) was measured. After 20 minutes, the results were evaluated and compared to control ( $\bullet$ , close circles) which consisted of the same concentrations of compounds, excluding APAP-SG conjugate. The blank samples without glutathione disulfide were also assessed - in the presence of the APAP-SG conjugate ( $\square$ , open squares) and without APAP-SG conjugate ( $\blacksquare$ , close squares).

**Fig. 3.** Inhibition of glutathione reductase (from rat hepatocytes lysate) by acetaminophen-glutathione conjugate (APAP-SG). Ratio of resultant glutathione reductase activities to control signal ( $8.7 \pm 0.5$  mU/ml) in samples treated with various concentrations of APAP-SG conjugate (0.37 mM, 0.74 mM, 1.48 mM, 2.96 mM and 3.70 mM). The absorbance decrease of NADPH ( $\lambda = 340$  nm) was monitored for 20 minutes. Results are expressed as mean  $\pm$  SD. (n = 2-4; \*, p < 0.05, \*\*\*, p < 0.001, compared to control)







